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Transplantation of islet allografts into type 1 diabetic recipients usually requires multiple pancreas donors to 
achieve insulin independence. This adds to the challenges of immunological monitoring of islet transplantation 
currently relying on surrogate immune markers in peripheral blood. We investigated donor origin and infiltra-
tion of islets transplanted in the liver of a T1D patient who died of hemorrhagic stroke 4 months after successful 
transplantation with two intraportal islet grafts combining six donors. Immunohistological staining for donor 
HLA using a unique panel of human monoclonal HLA-specific alloantibodies was performed on liver cryosec-
tions after validation on cryopreserved kidney, liver, and pancreas and compared with auto- and alloreactive 
T-cell immunity in peripheral blood. HLA-specific staining intensity and signal-to-noise ratio varied between 
tissues from very strong on kidney glomeruli, less in liver, kidney tubuli, and endocrine pancreas to least in 
exocrine pancreas, complicating the staining of inflamed islets in an HLA-disparate liver. Nonetheless, five 
islets from different liver lobes could be attributed to donors 1, 2, and 5 by staining patterns with multiple HLA 
types. All islets showed infiltration with CD8+ cytotoxic T cells that was mirrored by progressive alloreactive 
responses in peripheral blood mononuclear cells (PBMCs) to donors 1, 2, and 5 after transplantation. Stably 
low rates of peripheral islet autoreactive T-cell responses after islet infusion fit with a complete HLA mismatch 
between grafts and recipient and exclude the possibility that the islet-infiltrating CD8 T cells were autoreactive. 
HLA-specific immunohistochemistry can identify donor origin in situ and differentiate graft dysfunction and 
immunological destruction.
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INTRODUCTON
Islet transplantation is an effective treatment for 
brittle type 1 diabetes, and it allows most patients to 
achieve insulin independence. Transplanted b-cell mass 
is an important determinant of transplantation success. 
Single-donor transplantation is preferred, but islets from 
multiple donor organs and repeated transplantations are 
often required to achieve optimal function1. Although 
multidonor transplantation has improved transplantation 
outcome, it complicates understanding of improvements 
in isolation, transplantation, and immunosuppressive 
strategies. Identifying the fate of individual donor grafts 
is necessary to interpret changes in outcome with novel 
transplantation strategies. We previously reported on 
donor-specific alloreactive responses and recurrent auto-
immunity in multidonor islet transplants by investigating 
circulating immune cells2–5. However, it remains to be 
determined how immunity measured in peripheral blood 
relates to local immunity in islet transplantation.
Opportunities to investigate transplanted islets in situ 
are rare. Percutaneous techniques have reduced side 
effects of islet transplantation, while investigating an 
intraportal graft by transcutaneous liver biopsy has proven 
infeasible6. Risk of complications precludes repeated 
liver biopsies or surgical major biopsies to access trans-
planted islets. Therefore, in situ studies can only be per-
formed postmortem or on incidental patients who would 
require liver surgery. Identification of islet material in situ 
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is necessary to investigate donor-specific effects. Donor 
and recipient human leukocyte antigen (HLA) typing are 
usually known and differ in unmatched cases. We previ-
ously established a bank of human HLA-specific mono-
clonal antibodies (mAbs) to study humoral rejection 
in transplantation7. The ubiquitous expression of HLA 
class I would allow for employment of these antibodies 
to differentiate between recipient and individual donors 
by immunohistochemistry.
We investigated islet donor origin in the case of a 
61-year-old woman treated with islet transplantation for 
her brittle type 1 diabetes, who died of cerebral hemor-
rhage 4 months after receiving two intraportal islet grafts. 
Immunosuppression consisted of anti-thymoglobulin and 
methylprednisolone induction therapy and tacrolimus 
and mycophenolate mofetil maintenance therapy. She 
received islets from four donors in the first transplanta-
tion and from two donors in a second transplantation after 
6 weeks. All donors had complete HLA-A, -B, and -DR 
mismatch with the recipient. At time of death she had a 
functioning graft with nonfasting C-peptide of 2.02 ng/ml 
at 220 mg/dl glycemia while using 13 units of insulin per 
day. Auto- and alloreactive immune responses of T cells 
and antibodies were monitored per protocol before and 
after transplantation.
MATERIALS AND METHODS
Samples and Tissues
Blood samples were collected in sodium heparin tubes 
and serum tubes (BD Vacutainer, Breda, The Nether-
lands) containing silicate granulate for immune monitor-
ing before and at 4, 6, 9, and 12 weeks after transplantation 
with signed informed consent of the patient and according 
to the approved protocol2. Autopsies and studies on organ 
specimens were performed after obtaining oral informed 
consent from the patient’s family. For antibody optimi-
zation, cryopreserved kidney, liver, and pancreas tissue 
was obtained from leftover specimen selected to match 
allo-antibody HLA specificity. All materials were treated 
according to local and institutional regulations with 
approval from the Medical Ethical Committee of the Free 
University Brussels, Belgium, and in accordance with the 
2008 revised principles of the Declaration of Helsinki.
Peripheral Blood Immune Analysis
Autoimmune responses were determined blinded from 
clinical results. Lymphocyte stimulation tests were per-
formed before and at regular intervals after transplanta-
tion and on lymphocytes derived from different organs 
upon autopsy, as described before8. Briefly, 150,000 fresh 
peripheral blood mononuclear cells (PBMCs) per well 
or tissue-derived lymphocytes per well were cultured 
in 96-well round-bottom plates in Iscove’s modified 
Dulbecco’s medium (IMDM) with 2 mmol/L glutamine 
(Gibco, Paisley, Scotland) and 10% pooled human serum 
in the presence of antigen, interleukin-2 (IL-2; 35 U/ml; 
Novartis, Arnhem, The Netherlands), or medium alone 
in triplicates. After 5 days [3H]thymidine (0.5 µCi per 
well; DuPont NEN, Boston, MA, USA) was added, and 
[3H]thymidine incorporation was measured after 16 h 
on a beta-plate counter. Antigens analyzed included islet 
autoantibody-2 (IA-2; 10 µg/ml), glutamate decarboxylase- 
65 (GAD65; 10 µg/ml), insulin (25 µg/ml), and tetanus 
toxoid (“recall” antigen; 1.5 LF/ml). Results were inter-
preted as stimulation index (SI) compared to medium 
value and with a cutoff value of SI >3.
Alloreactive T-cell responses were determined by cyto-
toxic T-lymphocyte precursor (CTLp) assay and mixed 
lymphocyte reaction (MLR). The CTLp assay to determine 
cytotoxic T-cell alloreactivity was described previously9. 
Briefly, PBMCs were cultured in a limiting dilution assay 
(40,000 to 625 cells/well, 24 wells per concentration) 
with different irradiated stimulator PBMCs expressing 
HLA class I antigens matching b-cell grafts (50,000 cells/
well). Cells were cultured for 7 days at 37°C in 96-well 
round-bottom plates in RPMI-1640 medium (Gibco BRL, 
Paisely, UK) with 3 mmol/L L-glutamine, 20 U/ml IL-2, 
and 10% pooled human serum. Then Europium-labeled 
(Fluka, Buchs, Switzerland) graft HLA-specific target 
cells (5,000 cells/well) were added for 4 h. Wells were 
scored positive if the Europium release through target 
cell lysis exceeded spontaneous release +3× standard 
deviation. Quantification of CTLp frequencies was per-
formed by computer software10. In parallel, one-way mixed 
lymphocyte cultures were set up in triplicates in 96-well 
V-bottom plates (Costar, Cambridge, MA, USA) in 150 µl 
RPMI-1640 with 2 mmol/L L-glutamine (Gibco) and 10% 
pooled human serum. Responder cells (40,000) were 
incubated with 50,000 irradiated (3,000 rad) stimulator 
cells per well at 37°C/5% CO2. After 5 days, [3H]thymidine 
(1.0 µCi per well) was added, and [3H]thymidine incor-
poration was measured on a beta-plate counter (Wallac- 
LKB Betaplate 1205; Wallac, Turku, Finland) after 16 h. 
Proliferation in response to phytohemagglutinin was used 
as positive control. Results were interpreted as SI com-
pared to background value (responder only + stimulator 
only). Production of different cytokines was measured 
with Luminex technology using a human Th1/Th2 Bio- 
plex cytokine kit (Bio-Rad, Veenendaal, The Nether-
lands), including IL-2, IL-4, IL-5, IL-10, IL-12p70, 
IL-13, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), interferon-g (IFN-g), and tumor necrosis fac-
tor (TNF), according to the manufacturer’s protocol.
Screening for the presence of HLA class I- and class 
II-specific antibodies was performed on all available sam-
ples by enzyme-linked immunosorbent assay (ELISA; 
LAT class I&II; One Lambda, Canoga Park, CA, USA). 
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Islet cell autoantibodies (ICA), autoantibodies against 
IA-2 protein (IA-2A), and GAD were measured as 
described previously11. Briefly, ICA were determined 
by indirect immunofluorescence. IA-2A and GAD were 
determined by liquid phase radiobinding assays.
HLA-Specific Antibody Staining
Human mAbs specific for one or more HLA subtypes 
were selected from a previously described panel7,12. In 
short, heterohybridomas were created by Epstein–Barr 
virus transformation and cloning of B lymphocytes of 
multiparous women. The HLA specificities of the pro-
duced human mAbs were validated using a complement- 
dependent cytotoxicity test against PBMCs. HLA speci-
ficities were confirmed by flow cytometry on single HLA 
antigen-expressing cell lines13 and on single antigen 
beads14. Five antibodies were selected that could collec-
tively differentiate between the six islet donors on HLA 
typing (Tables 1 and 2). Antibodies were directly labeled 
with Alexa Fluor 488 (AF488) by Sanquin Blood Bank 
(Leiden, The Netherlands). Cryopreserved tissue was cut 
in consecutive 5-µm sections on a cryotome (Thermo 
Fisher Scientific, Waltham, MA, USA), air dried, and 
fixed in 4°C acetone for 10 min. Sections were stained 
overnight at 4°C with AF488-labeled HLA-specific 
antibodies (1:100). Then sections were stained with 
4¢,6-diamidino-2-phenylindole (DAPI; 1 ng/ml; Sigma-
Aldrich, Zwijndrecht, The Netherlands) and mounted 
with Mowiol (Sigma-Aldrich). For enhanced and multi-
fluorescence staining, primary staining was followed 
by a combination of rabbit anti-Alexa488 (Invitrogen, 
Bleiswijk, The Netherlands), guinea pig anti-insulin [poly-
clonal immunoglobulin G (IgG), in house], rabbit anti-
glucagon (polyclonal IgG, in house), mouse anti-CD45 
(Dako, Heverlee, Belgium), and/or mouse anti-CD8 
(NovaCastra, Rijswijk, The Netherlands) overnight at 4°C 
and, thereafter, anti-rabbit-Cy3 (Dako), anti-guinea pig-
Alexa 647 (Dako), and/or anti-mouse-AF488 (Dako), 
as applicable. These slides were mounted with DAPI 
(0.12 ng/ml) in fluorescence mounting medium (Dako). 
Positive HLA antibody staining was assessed by com-
paring fluorescence on insulin+ cells between islets in the 
same section and between HLA antibodies staining the 
same islet in consecutive sections, and cells were counted 
manually.
RESULTS
Immune Response Analysis
Immune responses were determined in peripheral 
blood before and after transplantation. Autoreactive T-cell 
Table 1. Islet Donor Identification by HLA Antibodies
Islet Lobe
BRO11F6
(D1,2,5)
JOK3H5
(D1,2,6)
SN230G6
(D4,5,6)
BVK1F9 
(D3)
DK7C11
(D1) Conclusion
1 LL + − + − − D5
2 LR + ± − − − D2
3 LR + + − − + D1
4 LR + ± + − ± D5
5 LR + − + − − D5
±, inconclusive; D, donor; LL, left liver lobe; LR, right liver lobe.
Table 2. Donor and HLA Antibody Staining Combinations
Antibodies
Donor HLA-A HLA-B BRO11F6 JOK3H5 SN230G6 BVK1F9 DK7C11
1 A10 (26)
A11
B12 (44)
B15 (62)
A11 B12 – – B12
2 A3
A19 (30)
B7
B40 (60)
A3 B40 – – –
3 A1
A10 (26) 
B8
B15 (62)
– – – B8 –
4 A2 B7
B17 (57)
– – A2/B17 – –
5 A2
A11
B15 (62)
B27
A11 – A2 – –
6 A2
A19 (29)
B13
B15 (62)
– B13 A2 – –
Patient A24 B18 A24 – – – –
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responses were tested by lymphocyte stimulation test 
to autoantigens and showed response to GAD65 (SI 13.2) 
before transplantation, but very low autoantigen-specific 
responses were shown after transplantation. Insulin auto-
antibodies were present before transplantation and remained 
unchanged thereafter. Alloreactive cytotoxic T-cell fre-
quency was reduced in the first 6 weeks after transplan-
tation. After 8 weeks, responses increased to HLA-A11 
(donors 1 and 5) and/or HLA-B62 (donors 1, 3, 5, and 
6). By week 12, additional responses emerged to donor 
1 (HLA-B44) and donors 2, 3, and/or 4 (HLA-A1, -A3, 
-A26, -B7, -B8, and/or HLA-B60) (Fig. 1). Alloreactive 
T-helper cell responses in MLR decreased after transplan-
tation correlating with increased IL-10 levels and reduced 
IFN-g/IL-10 ratio (Fig. 1). No alloreactive antibodies were 
measured before or after treatment (Tx).
Optimization of HLA-Specific Antibody Staining 
for Donor Determination
AF488-labeled HLA-specific antibodies were tested 
on HLA-typed human kidney, pancreas, and liver cryo-
sections. Great variation was seen in staining intensity 
within and between tissues. In the kidney, high intensity-
specific staining was seen on glomeruli and low staining 
on tubular areas. Staining on the pancreas was low, while 
islets stained slightly stronger than exocrine tissue. In the 
liver, parenchyma stained stronger than pancreas but also 
showed more background fluorescence, while scattered 
individual cells stained very strong (Table 3). Introduction 
to three-step staining with anti-Alexa488 secondary and 
Cy3-labeled tertiary antibody increased signal intensity 
FACING COLUMN
Figure 1. Alloreactive T-cell responses around transplanta-
tion. Immune suppression, graft function, and alloreactive 
T-cell responses monitored before and after transplantation. 
(A) Timing of immune suppression: thymoglobulin (horizontal 
bar), methylprednisolone pulses (X), mycophenolate mofetil 
daily dose (dashed line), and tacrolimus trough levels (squares). 
(B) Random C-peptide measurements. (C) Alloreactive cyto-
toxic T-cell precursor (CTLp) frequency to six human leukocyte 
antigen (HLA) mismatched stimulator target combinations was 
measured. Reactivity 8 weeks after transplantation (filled trian-
gle and square) suggests reactivity to HLA-A11 (donors 1 and 5) 
and/or B62 (donors 1, 3, 5, and 6). After 12 weeks, reactivity to 
stimulators depicted with open circles and diamonds suggests 
HLA-A3 or -B7 (both donors 2 and 4) reactivity, although A1, 
A26, B8, and/or B60 (donors 1, 2, and/or 3) is also possible. 
Further, changing reactivity to filled symbols suggests upcoming 
HLA-B44 reactivity matching donor 1. (D) Alloreactive T-helper 
proliferation was suppressed after transplantation. (E) Mixed 
lymphocyte reaction (MLR) cytokine response showed increas-
ing interleukin-10 (IL-10) production, but stable interferon-g 
(IFN-g) response leading to sharp decrease in IFN-g/IL-10 ratio. 
Symbols represent matched stimulators. Tx2, second transplant; 
TAC, tacrolimus; MMF, mycophenolate mofetil; PBMC, periph-
eral blood mononuclear cells; SI, stimulation index.
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and discrimination on pancreas sections and the patient’s 
liver sections containing endocrine pancreas tissue.
Postmortem Analysis
Postmortem, islet cell clusters were identified in the 
right and left liver lobes with varying mononuclear infil-
trates. Consecutive sections of four cryopreserved blocks 
scattered throughout the liver were used for in-depth 
analysis. First two to four sections of each series were 
used for negative control staining, leaving out individ-
ual primary antibodies and revealing low (AF488) and 
negligible (Cy3 and AF647) background fluorescence 
by secondary antibodies. Five consecutive sections were 
stained for specific HLA and insulin. From the left liver 
lobe, one of two assessed blocks revealed a single insu-
lin+ islet (Fig. 2 and Table 1, islet 1). An additional islet-
like area in slides used to optimize staining has been left 
out of further analysis since endocrine origin could not 
be confirmed by insulin or glucagon staining. Sections 
from the right lobe revealed an area with five islet cell 
clusters of which one cluster of only six cells was identi-
fied in a single section and could not be analyzed in detail 
(Table 1, islets 2–5). Thus, in total five pseudoislets were 
revealed and assessed.
HLA staining of insulin+ cells was low when compared 
to surrounding liver tissue, although individual insulin+ 
cells stained more clearly with HLA-specific antibodies. 
Groups of insulin+ cells were separated by cells staining 
strongly for the patient’s HLA. Islet cell clusters were 
scored as staining or not staining for the different HLA-
specific antibodies, which identified islets from donors 1, 
2, and 5 (Table 1). The chance of finding three islets of 
donor 5 with the relative donor contributions extrapolated 
from islet culture counting was 16%–21%, while donors 
in the first transplant were evenly distributed (Table 4).
Sections preceding and subsequent to HLA-stained 
sections were stained for glucagon, CD45, and CD8 to 
identify a-cells and infiltrating leukocytes. The ratio of 
glucagon to insulin+ cells varied greatly per islet ranging 
from 3:100 to 1:2 (Table 5). Very low numbers of a-cells 
were seen in two out of three islets from donor 5. Cell 
clusters containing glucagon, but not insulin+ cells, were 
not seen.
Infiltrate by CD45+ cells was observed in all islet cell 
clusters and CD8+ cells could account for 39%–57% of 
these infiltrates (Fig. 3 and Table 5). Most infiltrating cells 
surrounded the insulin+ cells, while insulin+ cells seemed 
to have disappeared around immune cells infiltrating the 
islets. Occasionally, CD45+ or CD8+ cells were in direct 
contact with insulin+ cells. Although the rate of infiltra-
tion varied between islet clusters, there was no apparent 
relation to donor origin.
DISCUSSION
We investigated the origin of identified islets in the 
liver of a patient with type 1 diabetes, who died 4 months 
after receiving islet transplants. We established HLA-
specific immunohistochemical staining on tissues of var-
ious organs observing tissue-specific variation in HLA 
expression and background fluorescence. Nonetheless, 
several transplanted islets were identified in the patient’s 
liver to originate from donors 1, 2, and 5. These islets 
were infiltrated with leukocytes including many cyto-
toxic T cells, which matches increasing frequency of 
CTLs specific to these donors measured in peripheral 
blood after transplantation.
We set up an immunohistochemical staining using 
HLA class I to evaluate donor origin of cells. Hereby, 
a broad range of chimeric combinations can be evalu-
ated including transplants from multiple donors, as pre-
sented in this article. Previously, islets from two donors 
were identified in a patient who died with longstanding 
graft function using laser dissection of islets retrieving 
DNA for HLA class II-based polymerase chain reac-
tion (PCR)15. With our current method, we investigated 
a more complex case receiving islets from six donors. 
Advantages of our method are that individual cells can be 
studied in combination with other markers and, despite 
Table 3. HLA-Specific Antibody Staining on Validation Tissues
Clone
HLA 
Specificity
Kidney 
Glomeruli
Kidney 
Tubuli Liver
Pancreas 
Endocrine
Pancreas 
Exocrine
W6/32 Pan-HLA +++ + ++(+) + 0
BRO11F6 A3/A11/A24 +++/+ ++/+ ++/+ +/0 0/0
JOK3H5 B12/B13/B21/ 
B40/B41/B70
+++/0 ++/++ +++/++ +/0 0/0
SN230G6 A2/B17 ++/0 +/0 +++/+ ++/+ +/0
BVK1F9 B8 ++/0 0/0 nd/nd nd/nd nd/nd
DK7C11 B12 +++/+ ++/+ +/0 nd/0 nd/0
Data presented as “specific stain”/“background nonspecific staining.” nd, no data.
0, no detectable staining; +, detectable staining; ++, intermediate staining; ++(+), good to strong staining; 
+++, strong staining.
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Figure 2. Identification of islet origin. Identification of donor 5 as source of islet 1 by staining with HLA-specific antibodies. Contrast-
optimized pictures showing multifluorescent staining of consecutive slides of islet 1 to insulin (green) and different HLA specificities 
(red). 4¢,6-Diamidino-2-phenylindole (DAPI) is shown in blue. Donors expressing the antibodies HLA specificity are listed below 
antibody clone names. Colors are pseudocolors. MoAb, monoclonal antibody.
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the complexity, fewer sections of an islet are required 
for identification. The major limitation of our method is 
restriction to cryopreserved material likely to be related 
to the superior preservation of the tertiary and quaternary 
structure of HLA molecules recognized by the mAbs.
Significant variation for the HLA staining was noted 
when optimizing HLA-specific staining in different organs. 
This was especially relevant since HLA expression was 
studied on transplanted pancreatic endocrine tissue with 
relatively low HLA expression in liver tissue with rela-
tively high autofluorescence, especially in the portal 
triad. Signal strength was optimized using secondary and 
tertiary staining to directly labeled human antibodies. 
This proved to be the most effective strategy to enhance 
staining with human antibodies in biotin-rich human tis-
sue. The exceptional combination of tissues did not allow 
optimal positive control slides; therefore, only negative 
control slides were taken along for secondary and tertiary 
staining. To improve judgment, identified islets were 
classified by three independent observers.
To our knowledge, this is the first time human allo-
reactive antibodies have shown to bind b-cells. Staining 
intensity was not particularly strong compared to kidney or 
liver tissue, but was stronger than exocrine pancreatic tissue 
in donor organ slides. Further, HLA staining in the iden-
tified transplanted islets varied between individual cells, 
which may result from inflammation. In inflamed islets of 
type 1 diabetes patients, hyperexpression of HLA has been 
described previously16,17. The limited number of identified 
islets did not allow comparison of HLA staining strength 
to lymphocytic infiltration in this patient. Nonetheless, 
our findings demonstrate that alloreactive human anti-
bodies can bind b-cells and may contribute to graft dem-
ise through antibody-dependent cellular cytotoxicity or 
complement-dependent cytotoxicity18.
We were able to identify donor origin of most islets 
identified in the cryopreserved patient’s liver sections. 
Identified islets came from both left and right liver lobes. 
Insulin+ cells of three out of six donors were traced in the 
liver, suggesting contribution of multiple donors as well 
as first and second transplants to graft function. Although 
identified islets were predominantly of donor 5, the num-
ber of identified islets is insufficient to prove selective 
donor survival.
All identified islets were surrounded by considerable 
numbers of immune cells including numerous cytotoxic 
CD8 T cells. Identification of T-cell specificity was not 
possible, since this requires prior knowledge of the HLA–
peptide combination involved17. The inverse pattern of 
leukocytes and insulin+ cells suggests these leukocytes 
may have destroyed parts of the graft. This would fit 
with rising donor-specific CTLs in peripheral blood after 
Table 4. Donor Characteristics
Gender
Age 
(Years) CMV Status
Culture 
Duration (Days)
Fraction of 
Transplant*
Donor 1 F 43 Negative 9 20% of Tx1
Donor 2 M 58 Positive 7 20% of Tx1
Donor 3 M 44 Positive 4 40% of Tx1
Donor 4 M 50 Positive 4 20% of Tx1
Donor 5 F 52 Positive 7 55%–60% of Tx2
Donor 6 F 67 Positive 4 40%–45% of Tx2
*Relative contribution of each donor to the transplants is calculated from b-cell counting 2–6 days 
before transplantation and predicted cell loss between b-cell counting and transplantation. Viability 
was >90% on the day of transplantation in all preparations; combined Transplant 1 (Tx1, donors 1 to 4) 
contained 863 million cells with 27% b-cells; combined Tx2 (donors 5 and 6) contained 282 million 
cells with 26% b-cells. F, female; M, male; CMV, cytomegalovirus.
Table 5. Islet Composition and Infiltration
Islet Lobe Donor
Cells/1,000 µm2 CD45/ 
Insulin Ratio
CD8/
CD45 (%)Insulin Glucagon CD45 CD8
1 LL D5 1.2 0.04 1.0 0.57 0.83 57
2 LR D2 0.91 0.45 1.4 0.55 1.5 41
3 LR D1
4 LR D5 0.80 0.29 0.23 0.09 0.29 39
5 LR D5 0.87 0.05 1.2 0.53 1.4 44
6* LR – 0.23 – 1.2 – 5.0 –
*Small cluster of insulin+ cells, only identified in single section. D, donor; LL, left liver lobe; LR, right liver lobe.
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transplantation. The partial destruction of the grafts may 
imply that these CTLs are hampered in their efficiency. 
This may be through the immune suppressive therapy, 
on which we previously reported upcoming alloreac-
tive CTL frequency after transplantation without corre-
lation to graft failure2. We further reported that tapering 
the immune suppression was accompanied by increasing 
avidity CTLs and loss of graft function19. Also, the infil-
trating cells may include alloreactive CD8 Tregs, which 
were previously identified to protect islets in an explanted 
pancreas graft20.
Autoimmunity was not observed in peripheral blood of 
our patient after transplantation. Probably recurrent auto-
immunity has been prevented or delayed by HLA class 
I mismatch between the donors and the recipient, which 
precludes direct recognition of islet autoantigens on the 
allograft. Indeed, this is accordant with the observation 
that all identified islets contained b-cells.
In conclusion, we established histological identifi-
cation of donor islet origin with human HLA-specific 
antibodies that specifically target transplanted human 
b-cells. This method was employed to investigate a case 
with multidonor islet transplantation to show identity and 
fate of multiple donor islets. We validated this method 
for multiple organs, suggesting it may also be effective to 
study other settings with multidonor chimerism.
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